Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
Mrowietz U, Barker J, Conrad C, Jullien D, Gisondi P, Flower A, Reddy J, Paris M, Picard H, Jardon S, Augustin M. Mrowietz U, et al. Among authors: paris m. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):348-355. doi: 10.1111/jdv.18689. Epub 2022 Nov 14. J Eur Acad Dermatol Venereol. 2023. PMID: 36300769 Clinical Trial.
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
Merola JF, Parish LC, Guenther L, Lynde C, Lacour JP, Staubach P, Cheng S, Paris M, Picard H, Deignan C, Jardon S, Chen M, Papp KA. Merola JF, et al. Among authors: paris m. J Am Acad Dermatol. 2024 Mar;90(3):485-493. doi: 10.1016/j.jaad.2023.10.020. Epub 2023 Oct 16. J Am Acad Dermatol. 2024. PMID: 37852306 Free article. Clinical Trial.
Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
Fiorillo L, Becker E, de Lucas R, Belloni-Fortina A, Armesto S, Elewski B, Maes P, Oberoi RK, Paris M, Zhang W, Zhang Z, Arkin L. Fiorillo L, et al. Among authors: paris m. J Am Acad Dermatol. 2024 Jan 23:S0190-9622(24)00108-7. doi: 10.1016/j.jaad.2023.11.068. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38266683 Free article.
Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Terui T, Okubo Y, Kobayashi S, Sano S, Morita A, Imafuku S, Tada Y, Abe M, Yaguchi M, Uehara N, Handa T, Tanaka M, Zhang W, Paris M, Murakami M. Terui T, et al. Among authors: paris m. Am J Clin Dermatol. 2023 Sep;24(5):837-847. doi: 10.1007/s40257-023-00788-2. Epub 2023 May 26. Am J Clin Dermatol. 2023. PMID: 37233897 Free PMC article. Clinical Trial.
Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Terui T, Okubo Y, Kobayashi S, Sano S, Morita A, Imafuku S, Tada Y, Abe M, Yaguchi M, Uehara N, Handa T, Tanaka M, Zhang W, Paris M, Murakami M. Terui T, et al. Among authors: paris m. Am J Clin Dermatol. 2024 Jan;25(1):165-167. doi: 10.1007/s40257-023-00825-0. Am J Clin Dermatol. 2024. PMID: 38060175 Free PMC article. No abstract available.
Germline proliferation trades off with lipid metabolism in Drosophila.
Rodrigues MA, Dauphin-Villemant C, Paris M, Kapun M, Mitchell ED, Kerdaffrec E, Flatt T. Rodrigues MA, et al. Among authors: paris m. Evol Lett. 2023 Nov 21;8(2):295-310. doi: 10.1093/evlett/qrad059. eCollection 2024 Apr. Evol Lett. 2023. PMID: 38525032 Free PMC article.
Measurement of the ^{13}C(α, n_{0})^{16}O Differential Cross Section from 0.8 to 6.5 MeV.
deBoer RJ, Febbraro M, Bardayan DW, Boomershine C, Brandenburg K, Brune C, Coil S, Couder M, Derkin J, Dede S, Fang R, Fritsch A, Gula A, Gyürky G, Hackett B, Hamad G, Jones-Alberty Y, Kelmar R, Manukyan K, Matney M, McDonaugh J, Meisel Z, Moylan S, Nattress J, Odell D, O'Malley P, Paris MW, Robertson D, Shahina, Singh N, Smith K, Smith MS, Stech E, Tan W, Wiescher M. deBoer RJ, et al. Among authors: paris mw. Phys Rev Lett. 2024 Feb 9;132(6):062702. doi: 10.1103/PhysRevLett.132.062702. Phys Rev Lett. 2024. PMID: 38394565
Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial.
Heming N, Renault A, Kuperminc E, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Leone M, Timsit JF, Misset B, Benali MA, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, François B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohé J, Loriferne JF, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Bounab R, Maxime V, Moine P, Bellissant E, Annane D; APROCCHSS investigators; CRICS-TRIGGERSEP network. Heming N, et al. Lancet Respir Med. 2024 May;12(5):366-374. doi: 10.1016/S2213-2600(23)00430-7. Epub 2024 Feb 1. Lancet Respir Med. 2024. PMID: 38310918 Clinical Trial.
660 results